Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.

Abstract:

:In 1968 the Food and Drug Administration (FDA) established the Adverse Event Reporting System (AERS) database containing data on adverse events (AEs) reported by patients, health care providers, and other sources through a spontaneous reporting system. FDA uses AERS for monitoring the safety of the drugs on the market after approval. Most statistical methods that are available in the literature to analyze large postmarket drug safety data for identifying drug-event combinations with disproportionately high frequencies are designed to explore signals of a single drug-AE combination, but not signals including a drug class or a group of AEs simultaneously. Those methods are also not designed to control type I error and are subject to high false discovery rates. In this paper, we first briefly review a recently developed method, known as the likelihood ratio test (LRT)-based method, which has been demonstrated to control the family-wise type I error and false discovery rates. By introducing a concept of weight matrix for the drugs (or for AEs), we then extend the LRT method for detecting signals including a class of drugs (or AEs) in addition to detecting signals of single drug (or AE). A simplified Bayesian method is also proposed and compared with LRT method. The proposed methods are applied to study the signal patterns of drug classes, namely, the gadolinium drug class for magnetic resonance imaging (MRI) and statins for hypercholesterolemia, over different time periods, using the datasets with only suspect drugs and with both suspect and concomitant drugs from the AERS database. The signals detected by the statistical methods can be confirmed by signals detected across different databases, existing medical evidence from research or regulatory resources, prospective biological studies, and also through simulation as illustrated in the application.

journal_name

J Biopharm Stat

authors

Huang L,Zalkikar J,Tiwari RC

doi

10.1080/10543406.2013.736810

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

178-200

issue

1

eissn

1054-3406

issn

1520-5711

journal_volume

23

pub_type

杂志文章
  • Statistical methods to analyze adverse events data of randomized clinical trials.

    abstract::The adverse events data of randomized clinical trials are often analyzed based on either crude incidence rates or exposure-adjusted incidence rates. These rates do not adequately account for an individual patient's profile of adverse events over the study period when an individual may remain in the trial after experie...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903105463

    authors: Siddiqui O

    更新日期:2009-09-01 00:00:00

  • A multilevel model for hierarchical, repeated, and overdispersed time-to-event outcomes and its estimation strategies.

    abstract::The aim of this article is to propose a multilevel combined model for repeated, hierarchical, and overdispersed time-to-event outcomes, extending the so-called combined model proposed by Molenberghs et al. (2010), and using three different estimation strategies: full likelihood, pseudo-likelihood, and Bayesian estimat...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.834914

    authors: Efendi A,Molenberghs G

    更新日期:2013-01-01 00:00:00

  • Assessment of antitumor activity for tumor xenograft studies using exponential growth models.

    abstract::In preclinical tumor xenograft experiments, the antitumor activity of the tested agents is often assessed by endpoints such as tumor doubling time, tumor growth delay (TGD), and log10 cell kill (LCK). In tumor xenograft literature, the values of these endpoints are presented without any statistical inference, which ig...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.481802

    authors: Wu J

    更新日期:2011-05-01 00:00:00

  • Estimating treatment effects in clinical crossover trials.

    abstract::Some current approaches to modeling crossover trials in two treatments are critically reviewed from the perspective of the practical requirements of the drug developer. Particular attention is paid to the AB/BA design, and the inadequacies of the once popular two-stage procedure are discussed in detail. The use of bas...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543409808835233

    authors: Grieve A,Senn S

    更新日期:1998-05-01 00:00:00

  • Frequency estimator for assessing of follow-on biologics.

    abstract::For approval of generic drugs, the U.S. Food and Drug Administration (FDA) requires the evidence of bioequivalence in average bioavailability be provided. This is based on the Fundmental Bioequivalence Assumption from FDA that if two drug products are shown to be bioequivalent, it is assumed that they are therapeutica...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.941985

    authors: Lu Y,Zhang ZZ,Chow SC

    更新日期:2014-01-01 00:00:00

  • Bayesian methods for the design and analysis of noninferiority trials.

    abstract::The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable alternative for evaluating treatment efficacy is through a noninferiority (NI) study where a test treatment is compared to an a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2015.1074920

    authors: Gamalo-Siebers M,Gao A,Lakshminarayanan M,Liu G,Natanegara F,Railkar R,Schmidli H,Song G

    更新日期:2016-01-01 00:00:00

  • On the establishment of equivalence acceptance criterion in analytical similarity assessment.

    abstract::For the assessment of biosimilarity of biosimilar products, the United States (US) Food and Drug Administration (FDA) proposed a stepwise approach for providing the totality-of-the-evidence of similarity between a proposed biosimilar product and a US-licensed (reference) product. The stepwise approach starts with the ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1265539

    authors: Wang T,Chow SC

    更新日期:2017-01-01 00:00:00

  • Design and sample size considerations for simultaneous global drug development program.

    abstract::Due to the potential impact of ethnic factors on clinical outcomes, the global registration of a new treatment is challenging. China and Japan often require local trials in addition to a multiregional clinical trial (MRCT) to support the efficacy and safety claim of the treatment. The impact of ethnic factors on the t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2012.701587

    authors: Huang Q,Chen G,Yuan Z,Lan KK

    更新日期:2012-09-01 00:00:00

  • On sample size calculation based on odds ratio in clinical trials.

    abstract::Sample size calculation formulas for testing equality, noninferiority, superiority, and equivalence based on odds ratio were derived under both parallel and one-arm crossover designs. An example concerning the study of odds ratio between a test compound (treatment) and a standard therapy (control) for prevention of re...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120016231

    authors: Wang H,Chow SC,Li G

    更新日期:2002-11-01 00:00:00

  • Dose finding with the sequential parallel comparison design.

    abstract::The sequential parallel comparison design (SPCD) is a two-stage design recommended for trials with possibly high placebo response. A drug-placebo comparison in the first stage is followed in the second stage by placebo nonresponders being re-randomized between drug and placebo. We describe how SPCD can be used in tria...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.924960

    authors: Wang JJ,Ivanova A

    更新日期:2014-01-01 00:00:00

  • Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studies.

    abstract::We assess the QT effect using an exposure-response model in a "thorough QT/QTc study" with a four-period crossover design in which the treatments are placebo, positive control, higher dose of investigational drug, and therapeutic dose of investigational drug. In the study, QTc interval values and the drug concentratio...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903582026

    authors: Hosmane B,Locke C,Chiu YL

    更新日期:2010-05-01 00:00:00

  • The analysis, interpretation, and presentation of quality of life data.

    abstract::All too often in clinical trials the assessment of quality of life is seen as a bolt-on study. Consequently insufficient consideration is often given to its design, collection, analysis and presentation, and its impact on the trial results and on clinical practice is minimal. In many trials quality of life is a key en...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120028506

    authors: Stephens R

    更新日期:2004-02-01 00:00:00

  • Equivalence tests for shelf life and average drug content in stability studies.

    abstract::Stability testing is a procedure frequently used in the pharmaceutical industry to estimate the shelf life of a drug. Hereby, a standard problem of interest is whether or not to pool a given number of batches to assign a single shelf life for the combined batches. In this paper, we propose two modified methods for the...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802287230

    authors: Djira GD,Hothorn LA,Tsong Y

    更新日期:2008-01-01 00:00:00

  • Optimal two-stage randomized multinomial designs for Phase II oncology trials.

    abstract::A new two-stage design is proposed that is suitable for early detection of the anticancer activity of experimental therapies in Phase II oncology trials. The endpoints of interest are response rate and early progression rate. The anticancer activity is defined by a positive signal in one endpoint and a non-negative si...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400902802417

    authors: Sun LZ,Chen C,Patel K

    更新日期:2009-01-01 00:00:00

  • Factorial dose-response studies using frequency and magnitude of dose.

    abstract::In the early stages of traditional drug development, the frequency of dosing (e.g., QD, BID, etc.) is typically determined by the pharmacokinetic properties of a compound. After an appropriate dose frequency is chosen, the magnitude of dose is then evaluated via parallel-group dose-response trials. For some drugs, how...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409608835141

    authors: Hafner KB,Ruberg SJ

    更新日期:1996-07-01 00:00:00

  • Exact inference for complex clustered data using within-cluster resampling.

    abstract::This paper introduces exact permutation methods for use when there are independent clusters of data with arbitrary within-cluster correlation. To eliminate the problem of clustering, we randomly select a data point from each cluster and for this now independent data, and calculate our test statistic and the associated...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543401003618884

    authors: Follmann D,Fay M

    更新日期:2010-07-01 00:00:00

  • On the designs of thorough QT/QTc clinical trials.

    abstract::A thorough QT trial is typically designed to test for two set of hypotheses. The primary set of hypotheses is for demonstrating that the test treatment will not prolong QT interval. The second set of hypotheses is to demonstrate the assay sensitivity of the positive control treatment in the study population. The conve...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.735762

    authors: Tsong Y

    更新日期:2013-01-01 00:00:00

  • Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.

    abstract::A common question in clinical studies is how to use historical data from earlier studies, leveraging relevant information into the design and analysis of a new study. Bayesian approaches are particularly well-suited to this task, with their natural ability to borrow strength across data sources. In this paper, we prop...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1226324

    authors: Li JX,Chen WC,Scott JA

    更新日期:2016-01-01 00:00:00

  • Linear structural equation model in analyzing quality-of-life-data from clinical trials.

    abstract::Assessment of quality of life (QOL) in clinical trials becomes a challenging task from the viewpoint of clinical biostatistics. The responses of the items for measuring QOL indices usually vary widely from patient to patient and from time to time. Measurement errors might be present in the responses of the items, and ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/bip-100101202

    authors: Siddiqui O,Ali MW

    更新日期:1999-11-01 00:00:00

  • Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studies.

    abstract::We study the statistical efficiency for rising-dose designs in the context of first-in-human studies. Specifically, we identify a class of crossover designs that are appealing in terms of both subject safety and statistical efficiency and, for a three-period, two-panel design in such a class, we compare its A-efficien...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.792827

    authors: Yan Z,Hosmane B,Locke C

    更新日期:2013-01-01 00:00:00

  • Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.

    abstract::It has been widely recognized that interim analyses of accumulating data in a clinical trial can inflate type I error. Different methods, from group sequential boundaries to flexible alpha spending functions, have been developed to control the overall type I error at prespecified level. These methods mainly apply to t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.901341

    authors: Chen LM,Ibrahim JG,Chu H

    更新日期:2014-01-01 00:00:00

  • Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment.

    abstract::We propose a new adaptive threshold detection and enrichment design in which the biomarker threshold is adaptively estimated and updated by optimizing a trade-off between the size of the biomarker positive population and the magnitude of the treatment effect in that population. Enrichment is based on an enrollment cri...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1832110

    authors: Wang T,Wang X,George SL,Zhou H

    更新日期:2020-11-11 00:00:00

  • Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information.

    abstract::When performing a pivotal clinical trial, it may be of interest to assess the probability of success (PoS) of that trial. Initially evaluated when the trial is designed, PoS can be updated as the trial progresses and new information about the drug effect becomes available. Such information can be external to the trial...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.972508

    authors: Rufibach K,Jordan P,Abt M

    更新日期:2016-01-01 00:00:00

  • Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control.

    abstract::In a clinical dose finding study with active control a new drug with several dose levels is compared with an active comparator drug. The main focus of such studies often lies on the estimation of a target dose that leads to the same efficacy as the control. This article investigates the finite sample properties of the...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.920343

    authors: Helms HJ,Benda N,Friede T

    更新日期:2015-01-01 00:00:00

  • Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.

    abstract::This article deals with seven special issues related to the assumptions, applicability, and practical use of formulas for calculating power or sample size, respectively, for comparative clinical trials with time-to-event endpoints, with particular focus on the well-known Freedman and Schoenfeld methods. All problems a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.1000546

    authors: Abel UR,Jensen K,Karapanagiotou-Schenkel I,Kieser M

    更新日期:2015-01-01 00:00:00

  • Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

    abstract::We extend the development of the expression of the Fisher information matrix in nonlinear mixed effects models for designs evaluation. We consider the dependence of the marginal variance of the observations with the mean parameters and assume an heteroscedastic variance error model. Complex models with interoccasions ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120019267

    authors: Retout S,Mentré F

    更新日期:2003-05-01 00:00:00

  • Impact of model misspecification at design (and/or) estimation step in population pharmacokinetic studies.

    abstract::The aim of this work is to quantitatively assess the impact of structural model misspecifications on the estimates of mean and interindividual variability of clearance in the context of population approaches. This assessment is conducted from simulated datasets. Our results show that impact magnitude of model misspeci...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120028516

    authors: Merlé Y,Aouimer A,Tod M

    更新日期:2004-02-01 00:00:00

  • Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.

    abstract::Noninferiority multiregional clinical trials (MRCTs) have recently received increasing attention in drug development. While a major goal in an MRCT is to estimate the global treatment effect, it is also important to assess the consistency of treatment effects across multiple regions. In this paper, we propose an intui...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1293075

    authors: Diao G,Zeng D,Ibrahim JG,Rong A,Lee O,Zhang K,Chen Q

    更新日期:2017-01-01 00:00:00

  • Group Sequential Design for Randomized Phase III Trials under the Weibull Model.

    abstract::In this article, a parametric sequential test is proposed under the Weibull model. The proposed test is asymptotically normal with an independent increment structure. The sample size for a fixed sample test is derived for the purpose of group sequential trial design. In addition, a multi-stage group sequential procedu...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.971165

    authors: Wu J,Xiong X

    更新日期:2015-01-01 00:00:00

  • Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.

    abstract::Using multistage adaptive group sequential test designs, the investigator may perform data-driven changes in the design during the course of the trial without inflation of the Type I error rate. This is possible, for example, through the use of the inverse normal method of combining the p-values from the separate stag...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120024196

    authors: Wassmer G

    更新日期:2003-11-01 00:00:00